RxDoctor Payments Data

Willie Lawrence, MD

Interventional Cardiology · Desoto, TXNPI 1851345466

Payments from drug & device makers

$3,666in general payments, 2019–2025

Across 119 payments — averaging $30.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Edwards Lifesciences$557
  • Medtronic$407
  • Amgen$345
  • Novartis$341
  • Novo Nordisk$316
  • AstraZeneca$295
  • plus $1K from 17 others

What the payments were for

  • Food & beverage$3,58698%
  • Education$802%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,666 in reported general payments places this provider in the 20th percentile of 686 interventional cardiology providers in Texas.

See all interventional cardiology providers in Texas

Medicare billing

Part B allowed, 2024
$36,515
Medicare patients
199
Services billed
464

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban78$71,860
EntrestoSacubitril/Valsartan50$52,196
XareltoRivaroxaban11$14,319
MultaqDronedarone Hcl12$9,580
Metoprolol Succinate274$3,390
Losartan Potassium206$1,961
Chlorthalidone111$1,556
Amlodipine Besylate293$1,508
Spironolactone205$1,271
Irbesartan82$826
Digoxin39$614
Ezetimibe36$593
Atorvastatin Calcium66$543
Hydralazine Hcl31$404
Potassium Chloride32$354

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$122$71,86078 claims
NovartisEntresto$341$52,19650 claims
Johnson & JohnsonXarelto$215$14,31911 claims
Sanofi-aventis U.S. LLCMultaq$58$9,58012 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 686 interventional cardiology providers in Texas.

Other interventional cardiology in Desoto

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →